Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2010-01-19 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex® trial. Strong anti-tumour response observed in all patients
Regulatory Filings Classification · 95% confidence The document is a press release announcing clinical trial results for PCI Biotech's Amphinex drug. It details the completion of a dose group and reports positive patient outcomes. As it is a general regulatory announcement regarding company operations and clinical progress that does not fit into specific financial reporting categories like 10-K or IR, it is classified as a Regulatory Filing (RNS).
2010-01-19 English
PCI Biotech rapporterer om vellykket fullføring av andre dosegruppe i fase I/II studien med Amphinex®. Kraftig effekt er observert på alle behandlede kreftsvulster
Regulatory Filings Classification · 95% confidence The document is a press release from PCI Biotech announcing the successful completion of a clinical trial dose group. It provides details on the study results, the technology (Amphinex), and future expectations. It is not a formal financial report, audit, or proxy statement, but rather a regulatory announcement regarding company operations and clinical progress, which falls under the general regulatory filing category (RNS) as it is a mandatory disclosure under the Norwegian Securities Trading Act.
2010-01-19 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.